NYSE:CHEHealthcare
Assessing Chemed (CHE) Valuation After Earnings Miss And Cautious 2026 Outlook
Chemed (CHE) is back in focus after its fourth quarter and full year 2025 results came in below analyst expectations, with softer margins, cautious 2026 guidance, and operational pressure at both VITAS and Roto Rooter.
See our latest analysis for Chemed.
That earnings miss and softer 2026 guidance appear to be weighing on sentiment, with a 7 day share price return of 13.72% and a year long total shareholder return of 31.39% pointing to fading momentum despite the buyback activity.
If Chemed's...